Schedule 13G ownership disclosure

CRINETICS PHARMACEUTICALS INC

Security class unavailable · CUSIP: 22663K107

Event date: 2019-06-10

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,244,904
Percent of class
6.8000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-20-014709
Form type
SC 13G
Filer
Crinetics Pharmaceuticals, Inc.
CIK
CIK 1658247
Filed
Jun 11, 2020
Reporting period
Jun 10, 2019
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub